表紙:中国のモキシフロキサシン市場の分析 (2021年~2025年)
市場調査レポート
商品コード
1010190

中国のモキシフロキサシン市場の分析 (2021年~2025年)

Investigation Report on China's Moxifloxacin Market 2021-2025

出版日: | 発行: China Research and Intelligence | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.72円
中国のモキシフロキサシン市場の分析 (2021年~2025年)
出版日: 2021年06月08日
発行: China Research and Intelligence
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

モキシフロキサシンは、Bayer Vital GmbHによって開発された第4世代の合成キノロン抗菌薬 (8-メトキシ-フルオロキノロン抗生物質) です。中国でも2002年に発売されました。

中国国内のモキシフロキサシンの販売額は、2016年から2019年にかけて拡大しましたが、2020年に急速に減少しました。2019年の販売額は18億8200万人民元、2020年は11億600万人民元 (41.23%減) となっています。2021年には新型コロナウイルス感染症 (COVID-19) 感染拡大が落ち着き、2025年にかけて拡大傾向が続くと見られています。

中国のモキシフロキサシン市場には、2020年時点では19社が参入しています。今後の更なる新規参入と共に、価格低下と販売量・販売額の拡大が見込まれています。

当レポートでは、中国のモキシフロキサシンの市場について分析し、製品の概略や許認可状況、全体的な市場規模の動向見通し、地域別の詳細動向、市場価格の動向見通し、主要企業のプロファイルと市場シェア、主な市場促進・抑制要因、新型コロナウイルス感染症 (COVID-19) の影響、といった情報を取りまとめてお届けいたします。

目次

第1章 モキシフロキサシンの関連概念

  • モキシフロキサシンの適応症
  • 中国国内のモキシフロキサシンの開発動向
  • 中国政府のモキシフロキサシンの承認状況
  • COVID-19が中国のモキシフロキサシン販売に与える影響

第2章 中国国内のモキシフロキサシンの販売動向 (2016年~2020年)

  • モキシフロキサシンの販売額
    • 全体的な販売額
    • 地域別の販売額
  • モキシフロキサシンの販売量
    • 全体的な販売量
    • 地域別の販売量
  • 中国国内のモキシフロキサシンの販売動向:剤形別 (2016年~2020年)
    • 注入剤
    • 錠剤
    • 点眼剤

第3章 中国のモキシフロキサシン主要メーカーの分析 (2016年~2020年)

  • 主要モキシフロキサシンメーカーの市場シェアの分析
    • 市場シェア:販売額ベース
    • 市場シェア:販売量ベース
  • Bayer Vital GmbH
    • 企業プロファイル
    • 中国でのモキシフロキサシンの販売動向
  • Nanjing Yoko Pharmaceutical Group Co., Ltd.
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chengdu Zhengkang Pharmaceutical Co., LTD.
  • Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.

第4章 中国のモキシフロキサシンの価格動向:主要メーカー別 (2020年~2021年)

  • Bayer Vital GmbH (AVELOX)
  • Nanjing Yoko Pharmaceutical Group Co., Ltd. (PRIMENOR)
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chengdu Zhengkang Pharmaceutical Co., LTD.
  • Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd. (Fengreineng)

第5章 中国のモキシフロキサシン市場の将来展望 (2021年~2025年)

  • 中国のモキシフロキサシン市場の動向を左右する要因
    • 中国のモキシフロキサシン市場に対するCOVID-19の影響
    • 市場の促進要因と機会
    • 市場の脅威と課題
  • 市場規模の予測
  • 市場動向の予測
図表

List of Charts

  • Chart Patent Information About Moxifloxacin Injection Registration in China
  • Chart Patent Information About Moxifloxacin Tablets Registration in China
  • Chart Patent Information About Moxifloxacin Eye Drop Registration in China
  • Chart Sales Value of Moxifloxacin Injection over the World
  • Chart Sales Value of Moxifloxacin Tablets over the World
  • Chart Sales Value of Moxifloxacin Eye Drop over the World
  • Chart Sales Value of Moxifloxacin Injection in China, 2016-2020
  • Chart Sales Value of Moxifloxacin Tablets in China, 2016-2020
  • Chart Sales Value of Moxifloxacin Eye Drop in China, 2016-2020
  • Chart Sales Value of Moxifloxacin Injection in China by Region, 2016-2020
  • Chart Sales Value of Moxifloxacin Tablets in China by Region, 2016-2020
  • Chart Sales Value of Moxifloxacin Eye Drop in China by Region, 2016-2020
  • Chart Sales Volume of Moxifloxacin Injection in China, 2016-2020
  • Chart Sales Volume of Moxifloxacin Tablets in China, 2016-2020
  • Chart Sales Volume of Moxifloxacin Eye Drop in China, 2016-2020
  • Chart Sales Volume of Moxifloxacin Injection in China by Region, 2016-2020
  • Chart Sales Volume of Moxifloxacin Tablets in China by Region, 2016-2020
  • Chart Sales Volume of Moxifloxacin Eye Drop in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Moxifloxacin Injection Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Moxifloxacin Tablets Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Moxifloxacin Eye Drop Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of AVELOX in China, 2016-2020
  • Chart Sales Value and Volume of PRIMENOR in China, 2016-2020
  • Chart Sales Value and Volume of Chengdu Tiantaishan Pharmaceutical Co., Ltd.'s Moxifloxacin in China, 2016-2020
  • Chart Sales Value and Volume of Chengdu Zhengkang Pharmaceutical Co., LTD.'s Moxifloxacin in China, 2016-2020
  • Chart Sales Value and Volume of Fengreineng in China, 2016-2020
  • Chart Referential Prices of AVELOX in China by Region, 2020-2021
  • Chart Referential Prices of PRIMENOR in China by Region, 2020-2021
  • Chart Referential Prices of Chengdu Tiantaishan Pharmaceutical Co., Ltd.'s Moxifloxacin in China by Region, 2020-2021
  • Chart Referential Prices of Chengdu Zhengkang Pharmaceutical Co., LTD.'s Moxifloxacin in China by Region, 2020-2021
  • Chart Referential Prices of Fengreineng in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Moxifloxacin Injection in China, 2021-2025
  • Chart Forecast on Sales Value of Moxifloxacin Tablets in China, 2021-2025
  • Chart Forecast on Sales Value of Moxifloxacin Eye Drop in China, 2021-2025
  • Chart Forecast on Sales Volume of Moxifloxacin Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Moxifloxacin Tablets in China, 2021-2025
  • Chart Forecast on Sales Volume of Moxifloxacin Eye Drop in China, 2021-2025
目次
Product Code: 2106518

Moxifloxacin is a fourth-generation synthetic quinolone antibacterial drug (8-methoxy-fluoroquinolone antibiotic) developed by Bayer Vital GmbH. It was approved for marketing by the FDA in December 1999. Moxifloxacin can be used to treat several infections, including respiratory infections, cellulitis, anthracnose, endocarditis, intra-abdominal infections, meningitis and tuberculosis. In 2002, Moxifloxacin tablets (400mg) were launched in China. In 2004, Moxifloxacin injection was launched for the treatment of adults suffering from upper and lower respiratory tract infections. In the first half of 2021, in addition to Bayer Vital GmbH, there are several manufacturer in the Moxifloxacin market in China, such as Nanjing Youke Pharmaceutical Co., Ltd., Chengdu Tiantaishan Pharmaceutical Co., Ltd., Chengdu Zhengkang Pharmaceutical Co., Ltd. and Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd.

CRI's survey data shows that the sales value of Moxifloxacin has grown steadily from 2016 to 2019 in China. In 2020, the sales value of Moxifloxacin fell by 41.23% in China, from CNY1.882 billion in 2019 to CNY1.106 billion in 2020. Due to the second batch of state-organized centralized procurement of medicines, and manufacturers of Moxifloxacin compete by reducing prices. Moxifloxacin of Bayer Vital GmbH dropped by 77.70%, and Moxifloxacin of Nanjing Youke Pharmaceutical Co., Ltd. dropped by 53.07%. The CAGR of the sales value of Moxifloxacin in 2016-2020 is -3.76% in China.

CRI predicts that with the effective relief of the COVID-19 epidemic, the sales of Moxifloxacin in the Chinese market will have a recovery growth in 2021-2025. In addition, there are 19 pharmaceutical companies that have entered the Chinese Moxifloxacin market by 2020. It is expected that the price of Moxifloxacin will decline with the addition of new manufacturers, and there is room for growth in sales volume and sales. At the same time, compared with similar drugs, Moxifloxacin has a broad antibacterial spectrum, strong curative effect and other advantages, so the sales volume of Moxifloxacin in China will maintain a growth trend.

Topics Covered:

  • The impact of COVID-19 on China's Moxifloxacin market
  • Sales value of China's Moxifloxacin 2016-2020
  • Competitive landscape of China's Moxifloxacin market
  • Prices of Moxifloxacin in China
  • Prices of Moxifloxacin in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Moxifloxacin market
  • Prospect of China's Moxifloxacin market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Moxifloxacin 1.1 Indications for Moxifloxacin

  • 1.2 Development of Moxifloxacin in China
  • 1.3 Governmental Approval of Moxifloxacin in China
  • 1.4 The Impact of COVID-19 on Moxifloxacin sales in China

2 Sales of Moxifloxacin in China, 2016-2020

  • 2.1 Sales Value of Moxifloxacin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Moxifloxacin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Moxifloxacin by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.3 Tablets
    • 2.3.3 Eye Drop

3 Analysis of Major Moxifloxacin Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Moxifloxacin Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Bayer Vital GmbH
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of AVELOX (Bayer Vital GmbH's Moxifloxacin) in China
  • 3.3 Nanjing Yoko Pharmaceutical Group Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of PRIMENOR (Nanjing Yoko Pharmaceutical Group Co., Ltd.'s Moxifloxacin) in China
  • 3.4 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Chengdu Tiantaishan Pharmaceutical Co., Ltd.'s Moxifloxacin in China
  • 3.5 Chengdu Zhengkang Pharmaceutical Co., LTD.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Chengdu Zhengkang Pharmaceutical Co., LTD.'s Moxifloxacin in China
  • 3.6 Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Fengreineng (Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.'s Moxifloxacin) in China

4 Prices of Moxifloxacin for Different Manufacturers in China, 2020-2021

  • 4.1 Bayer Vital GmbH (AVELOX)
  • 4.2 Nanjing Yoko Pharmaceutical Group Co., Ltd. (PRIMENOR)
  • 4.3 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • 4.4 Chengdu Zhengkang Pharmaceutical Co., LTD.
  • 4.5 Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd. (Fengreineng)

5 Prospect of Chinese Moxifloxacin Market, 2021-2025

  • 5.1 Influential Factors of Chinese Moxifloxacin Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Moxifloxacin Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend